Gastric microbiota and probiotics opportunities using L.reuteri DSM17648 for helicobacter pylori eradication in children

Results: H. pylori decreased microbial diversity associated with inflammation and focal mucosal atrophy. H. pylori eradication was achieved on Lr monotherapy in 50% after 28 and 60% after 56days, on adjuvant Lr therapy – 60% after 28 and 77.8% after 56days, in placebo group – 68.8% after 28 and 56days. Clinical manifestation, inflammatory and atrophic changes during Lr treatment significantly and reliably decreased.

Conclusion: Lr monotherapy is comparable in effectiveness to a standard eradication therapy.

Keywords: H. pylori, non-Helicobacter gastric microbiota, probiotics, L. reuteri

Shopping Cart
Scroll to Top

New Name. New Website.

We have changed our name from Nouveau Health to Nouveau Healthcare and we've moved from nouveauhealth.co.uk to nhinnovations.com.

We hope you enjoy using your new platform.